Comparative Pharmacology
Head-to-head clinical analysis: CU 7 versus XULANE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CU 7 versus XULANE.
CU-7 vs XULANE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
The Cu-7 intrauterine device (IUD) releases copper ions, which inhibit sperm motility and viability, and alter the endometrial environment to prevent implantation.
Ethinyl estradiol and norelgestromin (the active metabolites of norgestimate) suppress gonadotropin release, inhibiting ovulation and increasing cervical mucus viscosity, impairing sperm penetration.
50 mg orally once daily
Apply 1 patch (20 cm² containing 600 mcg ethinyl estradiol and 6 mg norelgestromin) transdermally once weekly for 3 weeks, followed by 1 patch-free week.
None Documented
None Documented
Not applicable; intrauterine device with no systemic elimination half-life. Copper release is continuous with a rate of approximately 38 µg/day, declining over time.
Terminal elimination half-life is 4.5 hours; in severe renal impairment (CrCl <30 mL/min), half-life may be prolonged up to 12-15 hours, requiring dose adjustment.
Primarily fecal (80-90%) as unabsorbed copper; negligible renal excretion (<1%).
Primarily renal (approximately 60-70% as unchanged drug), with biliary/fecal elimination accounting for 20-30%.
Category C
Category C
Contraceptive
Contraceptive